Prescription Ibuprofen Recalled Due to Failed Impurity Specifications
Dr. Reddy's Laboratories is recalling IBU (Ibuprofen) 800 mg prescription tablets nationwide due to failed quality specifications. Testing found unknown impurities exceeding acceptable limits.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall for a prescription medication with unknown impurities exceeding quality specifications. The hazard represents a risk of harm from pharmaceutical impurities, matching the rubric criterion for risk-of-harm products where injury has not yet been reported.
Plain-English summary
Dr. Reddy's Laboratories, Inc. is recalling IBU (Ibuprofen) Tablets, USP, 800 mg (prescription only) distributed nationwide in the USA and Puerto Rico. The recall affects 103,298 bottles in two package sizes: NDC 55111-684-01 (100-tablet bottles) and NDC 55111-684-05 (500-tablet bottles), with expiration dates ranging from May 2026 through March 2027.
The recall was initiated because testing identified failed impurities/degradation specifications. Test results showed unknown impurity levels of 0.13% and 0.11%, both exceeding the acceptable specification limit of 0.10%.
Patients currently taking these tablets should not discontinue use without consulting their healthcare provider. Consumers who have purchased affected bottles should contact their pharmacy or healthcare provider immediately to confirm whether they have an affected lot. The FDA classifies this as a Class II recall.
The recalled product
- Product
- IBU (IBUPROFEN)
- Brand
- IBU
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Category
- Drug
- Hazard
- unknown-impurity
- degradation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- a) NDC 55111-684-01 Lots C2207525
- Exp 5/31/2026
- C2212902
- Exp 11/30/2026. b) NDC 55111-684-05 Lots C2207526
- C2210751
- C2210752
- Exp 9/30/2026
- C2212765
- C2212766
- Exp 11/30/2026
- C2301027
- C2301063
- C2301187
- C2301188
- C2301247
- Exp 12/31/2026
- C2301356
- C2301388
- C2301494
- C2301478
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · IBU
- LowIbuprofen 600 mg tablets recalled for failed tablet specifications
FDA (Drugs) · 2024-11-27
- HighPrescription Ibuprofen Tablets Recalled for Excessive Unknown Impurities
FDA (Drugs) · 2024-09-04
- HighIBU Prescription Ibuprofen Tablets Recalled for Failed Impurity Specifications
FDA (Drugs) · 2024-09-04
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27